These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34895223)

  • 1. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.
    Maeda H; Okabe A; Sakakura K; Ng DB; Akazawa M
    BMC Health Serv Res; 2021 Dec; 21(1):1329. PubMed ID: 34895223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J; Lan T; Lu H; Pan J
    PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan.
    Okabe A; Hayashi H; Maeda H
    Curr Oncol; 2023 Feb; 30(2):1776-1783. PubMed ID: 36826098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2016 May; 50(3):361-367. PubMed ID: 30227073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
    Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of market prices for drugs under Japan's national health insurance.
    Mamiya H; Igarashi A
    J Med Econ; 2021; 24(1):1109-1114. PubMed ID: 34448667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 8. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
    Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
    Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery Prices.
    Fukumoto D; Tsuyuki A; Suzuki T
    Ther Innov Regul Sci; 2017 Sep; 51(5):597-603. PubMed ID: 30231688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
    Kawakami A; Masamune K
    Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
    Zhou J; Lu H; Pan J
    Int J Health Policy Manag; 2024; 13():8150. PubMed ID: 38618837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
    Heine RJSD; Thielen FW; Mathijssen RHJ; van Leeuwen RWF; Franken MG; Uyl-de Groot CA
    PLoS One; 2024; 19(2):e0293264. PubMed ID: 38300937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of New Drug Accessibility and Price Between Japan and Major European Countries.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2017 Sep; 51(5):604-611. PubMed ID: 30231682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
    Rossini EE; Galeone C; Lucchetti C; Jommi C
    Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
    Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
    BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy.
    Shibata S; Fukumoto D; Suzuki T; Ozaki K
    Ther Innov Regul Sci; 2020 May; 54(3):544-551. PubMed ID: 33301139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
    Chen CL; Chen L; Yang WC
    BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT; Mills M; Kanavos P
    Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
    Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
    Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.